ViroMed Steps Up Global Ambitions With New Gene Therapy Pipeline
Executive Summary
ViroMed, which is conducting late phase clinical trials of its gene therapy, VM202, in the US, hopes to emerge as a top global DNA-based gene therapy company. It has a promising pipeline of CAR-T and DNA therapies and has hired a team of global experts to propel its efforts.
You may also be interested in...
Interview: ViroMed On Pricing, Manufacturing World’s First Broadly Used Gene Therapy
The head of global business strategy at ViroMed, one of the gene therapy companies nearing the commercial stage in the US, talks exclusively to Scrip about the South Korean biotech’s strategies, including for pricing and manufacturing, which are emerging as key considerations for developers.
ViroMed's Plasmid DNA Facility Buy Addresses Key Potential US Regulatory Hurdle
ViroMed, which is progressing Phase III clinical trials for its gene therapy VM202 in the US, has acquired a plasmid DNA manufacturing facility in San Diego, a move that will enable the South Korean biotech to provide stable supplies of the product if approved, and addressing a major uncertainty for gene therapies seeking regulatory approval from the FDA.
Korea Stepping Up IO R&D To Catch Up With Global Players, Trends
Immuno-oncology deals and R&D by South Korean companies are picking up speed as they are put more focus on the hot sector in line with global trends.